Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC targets spammers

This article was originally published in The Tan Sheet

Executive Summary

A U.S. district court in Illinois ordered a halt to spam e-mails and bogus claims for Kaycon's hoodia weight-loss supplements and human growth hormone anti-aging products after FTC filed a complaint against the firm. Kaycon falsely claimed its hoodia products would cause rapid and substantial weight loss, "including as much as 40 pounds in a month" and its HGH products would "turn back or reverse the aging process," among other claims, FTC states. The federal court ordered an ex parte temporary restraining order and asset freeze of the firm, and will decide after an Aug. 27 hearing whether to extend the asset freeze until the FTC's case is resolved. The FTC ultimately seeks to permanently bar the firm from further violations and it forfeit its "ill-gotten gains"...

You may also be interested in...

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another

Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.

EU ‘Structured Dialog’ Offers Opportunity To Secure Supply

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts